Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-39931
Volltext verfügbar? / Dokumentlieferung
Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.
Titel: Clinical Data on Immunotherapy in Breast Cancer
VerfasserIn: Radosa, Julia Caroline
Stotz, Lisa
Müller, Carolin UdsID
Kaya, Askin Canguel UdsID
Solomayer, Erich-Franz
Radosa, Marc Philipp
Sprache: Englisch
In:
Titel: Breast Care
Bandnummer: 15
Heft: 5
Seiten: 450-469
Verlag/Plattform: Karger
Erscheinungsjahr: 2020
Freie Schlagwörter: Breast cancer
Immunotherapy
Immune checkpoint inhibition
CAR T-cell therapy
Tumor vaccination
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Background: Breast cancer has traditionally been considered to have a low immunogenic potential compared to other tumor entities. Summary: The most extensively studied immunotherapeutic agents for breast cancer to date are immune checkpoint inhibitors, with the results of the IMpassion130 trial leading to the approval of atezolizumab plus nab-paclitaxel for first-line treatment of programmed cell death ligand 1-positive, metastatic, triple-negative breast cancer, and studies in earlier stages have yielded promising results. Other immunotherapeutic options being assessed in phases 2 and 3 trials include vaccine-based therapies and treatment with anti-human epidermal growth factor receptor 2 (H-directed immune-linked antibodies) and substances evaluated in early clinical trials as cellular therapies (adoptive cell therapy and chimeric antigen receptor T cells). Key Messages: Immunotherapy is an emerging modality for the treatment of breast cancer, as evidenced by the plethora of preclinical and clinical concepts and ongoing trials. Early studies established the role of immunotherapeutic agents in the metastatic setting. Ongoing studies will expand our knowledge about the timing of administration, best partners for combination therapy, and predictive biomarkers to guide immunotherapy for breast cancer.
DOI der Erstveröffentlichung: 10.1159/000511788
URL der Erstveröffentlichung: https://doi.org/10.1159/000511788
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-399310
hdl:20.500.11880/35937
http://dx.doi.org/10.22028/D291-39931
ISSN: 1661-3805
1661-3791
Datum des Eintrags: 9-Jun-2023
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Frauenheilkunde
Professur: M - Prof. Dr. E.-F. Solomayer
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.